ライフサイエンスコーパス: radionuclide

1 it as a substitute for a generic therapeutic radionuclide.

2 the associated energies of the beta-emitting radionuclide.

3 ve fluorescent dye and via a chelator with a radionuclide.

4 herapeutic and the physical half-life of the radionuclide.

5 therapy, brachytherapy, and various injected radionuclides.

6 f the half-lives of several other long-lived radionuclides.

7 been synthesized for sensing alpha-emitting radionuclides.

8 and (177)Lu are widely used beta(-)-emitting radionuclides.

9 wth kinetics of radium and its decay product radionuclides.

10 itative toxicity assessment of environmental radionuclides.

11 ear wastewaters contaminated with metals and radionuclides.

12 peptides labeled with a variety of different radionuclides.

13 dose rates remained dominated by background radionuclides.

14 lly the relative response ratios for these 2 radionuclides.

15 es in energy deposition patterns between the radionuclides.

16 uence the oxidation state of redox-sensitive radionuclides.

17 simultaneous preconcentration of all target radionuclides.

18 tumor uptake for immunoPET imaging with both radionuclides.

19 species with positron- or gamma-ray-emitting radionuclides.

20 ted for image-guided delivery of therapeutic radionuclides.

21 or the speciation-sensitive ecotoxicology of radionuclides.

22 the half-lives of (211)At and shorter-lived radionuclides.

23 s from delivery of diagnostic or therapeutic radionuclides.

24 , the short half-lives of the currently used radionuclides (11)C (20.4 min) and (18)F (109.8 min) may

25 evaluate the S values of 9 positron-emitting radionuclides ((11)C, (13)N, (15)O, (18)F, (64)Cu, (68)G

26 Exchanging the Gd(3+) ion for the radionuclide, (111)In, also allowed detection by single-

27 dies, complementing the conventional halogen radionuclide (124)I.

28 They were labelled with the radionuclide (131) I (beta(-) /gamma emitter, t1/2 8.02

29 -like polypeptide (ELP) are labeled with the radionuclide (131)I to form an in situ hydrogel that is

30 nd (232)Th and their progeny) and artificial radionuclides ((137)Cs) in various honey samples, as wel

31 heranostic nanoparticle delivering the model radionuclide (177)Lu based on the versatile lipid-calciu

32 oimmunotherapy (PRIT) with the beta-emitting radionuclide (177)Lu is an attractive approach to treat

33 and radiolabeled with the positron-emitting radionuclide (64)Cu (half-life, 12.7 h).

34 nating QD system by doping positron-emitting radionuclide (64)Cu into CdSe/ZnS core/shell QDs via a c

35 Herein, a radionuclide-(64) Cu-labeled doxorubicin-loaded polydopa

36 beta-emitters ((3)H, (14)C, (35)S), gaseous radionuclides ((85)Kr, (133)Xe, (135)Xe) or radionuclide

37 Recently, the transition metal radionuclide (89)Zr has attracted increasing interest fo

38 was radiolabeled with the positron-emitting radionuclide (89)Zr.

39 In addition to (134,137)Cs, the radionuclide (90)Sr was estimated to contribute up to ap

40 had been printed, SPECT/CT acquisitions of 3 radionuclides ((99m)Tc, (177)Lu, and (131)I) were obtain

41 d the source-specificity of (131)I make this radionuclide a potentially valuable tracer in wastewater

42 per cell increased over the first 3 h after radionuclide administration and decreased thereafter.

43 G labeled with near-infrared fluorophores or radionuclides allowed us to noninvasively detect active

44 of the tumor dose originates from cell-bound radionuclides, an increase in the specific activity woul

45 ped to "arm" the antibodies with any desired radionuclide and specific activity, calculate the absorb

46 Although the underlying radionuclide and the related collimator have a major inf

47 measure the whole-body distribution of this radionuclide and to estimate radiation dose to various o

48 Natural radionuclides and (137)Cs in twenty seven honeys produce

49 13 mSv a(-1) (14%) was solely from the FDNPP radionuclides and below the 1 mSv a(-1) benchmark for pu

50 diagnostic and therapeutic payloads such as radionuclides and drugs into neoplastic masses.

51 ication, which is critical when working with radionuclides and is similarly beneficial for general sy

52 n contrast to conventional RID/RIT where the radionuclides and oncotropic vector molecules are delive

53 uitable host phase for the immobilization of radionuclides and other harmful elements, as is frequent

54 ation state distribution for redox sensitive radionuclides and other metal ions is challenging at tra

55 ete, coincides with global spikes in fallout radionuclides and particulates from fossil fuel combusti

56 reporters for bioluminescence, fluorescence, radionuclide, and magnetic resonance imaging (MRI) have

57 This article reviews optical imaging of both radionuclide- and beam-based ionizing radiation from hig

58 We performed equilibrium radionuclide angiography (ERNA) before and 6 mo after CR

59 evolution and development of the theranostic radionuclide approach to the management of neuroendocrin

60 Some of the understudied radionuclides are of radiological concern, others are pr

61 Radionuclides are present in groundwater at contaminated

62 ds that allow single-cell optical imaging of radionuclides are reviewed.

63 illing moieties, including toxins, drugs, or radionuclides, are chemically or genetically linked to m

64 in the event of internal exposures to these radionuclides at nuclear facilities and nuclear power pl

65 ranostic agents, which enables precision and radionuclide-based combination tumor therapy.

66 other prostate cancer imaging probes and non-radionuclide-based imaging approaches.

67 teins have attracted attention as probes for radionuclide-based molecular imaging.

68 peptides by conjugation with fluorophores or radionuclide-bearing moieties is an effective and common

69 (161)Tb is a promising radionuclide because it combines the advantages of a med

70 ovide new information about dynamic iron and radionuclide biogeochemistry throughout realistic sedime

71 The overall rates of prior radionuclide bone imaging were 78%, 76%, and 66% for pro

72 environmental transport and uptake of heavy radionuclides by marine species.

73 aken together with the energy spectra of the radionuclides can account for some of the differences in

74 kov radiation generated by positron-emitting radionuclides can be exploited for a molecular imaging t

75 The positron-emitting radionuclide carbon-11 ((11)C, t1/2 = 20.3 min) possesse

76 nds requires optimization with regard to the radionuclide-chelating agent and the linker moiety betwe

77 However, increased radionuclide concentration alters its speciation, render

78 u-lilotomab satetraxetan is a novel antibody-radionuclide conjugate currently in a phase 1/2a first-i

79 b satetraxetan is a novel anti-CD37 antibody-radionuclide conjugate currently in phase 1/2a.

80 u-lilotomab satetraxetan is a novel antibody radionuclide conjugate currently tested in a phase 1/2a

81 vestigated as a model system for engineering radionuclide containing materials through utilization of

82 Many studies have addressed the radionuclide content in mushrooms, almost exclusively th

83 cations for the interpretation of cosmogenic radionuclide data and resulting total solar irradiance e

84 alpha-Emitting radionuclides deposit a large amount of energy within a

85 h evaluations of the molar fractionations of radionuclides deposited in the soil relative to modeled

86 Both radionuclide detection and fluorescence imaging may prov

87 However, most radionuclide detection methods have spatial resolution i

88 etection limit capability improves, accurate radionuclide determination requires highly effective sep

89 Radionuclides differ from conventional chemical tracers

90 renkov luminescence imaging (CLI) of in vivo radionuclide distribution in small animals, a method pro

91 the physicochemical behavior of the produced radionuclides during operation, and in terms of an inter

92 s with technetium-99, one of the most mobile radionuclides encountered.

93 Finally, the article examines whether radionuclide examinations might be able to play an expan

94 Among the beta(+)-emitting radionuclides, fluorine-18 ((18)F) is the isotope of cho

95 Zirconium-89 is an effective radionuclide for antibody-based positron emission tomogr

96 Selecting a radionuclide for theranostic purposes generally starts b

97 210)Po and (90)Sr, two of the most important radionuclides for radiological dose from the ingestion p

98 tibody-related therapeutics labeled with PET radionuclides for theranostic purposes in patients.

99 uired to evaluate the efficacy of individual radionuclides for theranostic purposes, taking cell geom

100 agnitude of the transfer to milk of elements/radionuclides for which no relevant data have yet been i

101 atrix removal procedure to purify the target radionuclides from a urine sample followed by an automat

102 eiving a considerable input of anthropogenic radionuclides from nuclear reprocessing facilities locat

103 Decontamination of the dispersed radionuclides from seawater and soil, due to the huge am

104 Stable-element proxies show that radionuclides from the Trinity device were chemically, b

105 coronary intervention underwent predischarge radionuclide gated heart pool scan to assess ventricular

106 , Trinity, are reliable chemical proxies for radionuclides generated during the explosion.

107 scales by coupling high-precision cosmogenic radionuclide geochronology and rigorous numerical modeli

108 devastating Tsunami, a damageable amount of radionuclides had dispersed from the Fukushima Daiichi's

109 The choice of (177)Lu as a model radionuclide has allowed in vivo anticancer therapy in a

110 These results demonstrate that this radionuclide has been transported relatively long distan

111 rapy of solid tumors using antibody-targeted radionuclides has been limited by low therapeutic indice

112 abeling of somatostatin analogs with various radionuclides has led to a revolution in patient managem

113 s is in agreement with results obtained from radionuclides heavier than iron produced by neutron capt

114 Appropriate Use Criteria (AUC) published for radionuclide imaging (RNI), stress echocardiography (Ech

115 a scintillating balloon-enabled fiber-optic radionuclide imaging (SBRI) system to improve the sensit

116 he functional tumor characteristics shown by radionuclide imaging allow for more accurate staging and

117 n human medical imaging, with an emphasis on radionuclide imaging and MRI.

118 Both radionuclide imaging and near-infrared fluorescent (NIRF

119 feasibility of using anti-PD-L1 antibody for radionuclide imaging and radioimmunotherapy and highligh

120 ity of the 2009 Appropriate Use Criteria for radionuclide imaging and whether physicians at various l

121 response to etanercept could be monitored by radionuclide imaging in arthritic mice.

122 ted alterations of molecular phenotype using radionuclide imaging is a noninvasive approach to strati

123 ty for the 2009 Appropriate Use Criteria for radionuclide imaging is modest, and there is considerabl

124 y was to evaluate the feasibility of in vivo radionuclide imaging of PDGFRbeta expression using an Af

125 Breast-dedicated radionuclide imaging systems show promise for increasing

126 Radionuclide imaging techniques are both useful and reli

127 To evaluate the usefulness of radionuclide imaging techniques for presurgical evaluati

128 Radionuclide imaging with [(18)F]BF4(-) (PET/CT) was com

129 noninvasive imaging using echocardiography, radionuclide imaging, and cardiac magnetic resonance enh

130 w and regional metabolism can be assessed by radionuclide imaging, especially SPECT and PET.

131 limitations of broad clinical application of radionuclide imaging, this technology has a great impact

132 al resolution of MRI with the sensitivity of radionuclide imaging.

133 e measurements, also taking into account the radionuclide impurity of (177m)Lu and build-up of second

134 e contribution to the absorbed dose from the radionuclide impurity of (177m)Lu was negligible.

135 the radioactivity, reduce the uptake of the radionuclide in healthy nontarget tissues, and facilitat

136 rapidly expanding because of the use of this radionuclide in radiotracers for positron emission tomog

137 n, resulting in a certain percentage of free radionuclide in the body.

138 Radionuclide in vivo visualization of PDGFRbeta expressi

139 portant medium of transport for the released radionuclides in a respirable form.

140 for the incorporation of Cu(I) or (64)Cu(I) radionuclides in covellite nanocrystals (CuS NCs).

141 or the rapid determination of hard-to-detect radionuclides in environmental and biological samples fo

142 6/52/Euratom updates the emergency limits on radionuclides in foods including (210)Po and (90)Sr, two

143 oated TiO2 nanoparticles and clinically used radionuclides in mice and colocalization in tumours resu

144 considered in the migration model of Cs and radionuclides in the current environment surrounding the

145 this has clear implications for the fate of radionuclides in the environment.

146 the 1950s and 1960s, due to high transfer of radionuclides in the lichens-reindeer-human food chain.

147 s, (134)Cs, (131)I, and other gamma-emitting radionuclides in the ocean, but minor work was done rega

148 that a continuous surveillance of artificial radionuclides in the Pacific Ocean is still required.

149 soluble reagents (e.g., drugs, enzymes, and radionuclides) in microvolume liquid plugs to targeted b

150 e site preferences and stability of analogue radionuclide incorporation for Sr, Co, Eu, and U.

151 murine anti-PD-L1 antibody conjugated to the radionuclide Indium-111 ((111)In) for imaging and biodis

152 a and (18)F stand out because of the ease of radionuclide introduction (e.g., (68)Ga isotope) or opti

153 es deposited in the soil relative to modeled radionuclide inventories, we confirm the initial source

154 o managing this highly mobile and long-lived radionuclide is immobilization into micro- and meso-poro

155 The short-lived (26)Al radionuclide is thought to have been admixed into the in

156 s a confounding factor, because any effluxed radionuclide is trapped in the droplet.

157 , diagnostic accuracy with positron-emitting radionuclides is greater than 90%.

158 accelerators, nuclear reactors and clinical radionuclides, it has been used in applications such as

159 reover, dosimetry calculations revealed that radionuclide-labeled anti-PD-L1 antibody yielded tolerab

160 cept involves the use of very low doses of a radionuclide-labeled compound for imaging studies or for

161 , as well as the pharmacodynamic effect of a radionuclide-labeled EGFR inhibitor in situ.

162 d the first-in-human treatment with an alpha-radionuclide-labeled PSMA ligand.

163 mido derivative of a DOTA chelator, enabling radionuclide labeling, (1)(1)(1)In for SPECT imaging and

164 of colloids may facilitate the transport of radionuclides leaked from near surface waste sites and g

165 aracterization of (177)Lu-LCP has shown that radionuclide loading can be increased by several orders

166 Emission of radiation from the RPT radionuclide may disturb coincidence detection and impai

167 de derivatives radiolabeled with therapeutic radionuclide may offer a new strategy for the treatment

168 Molecular radiotherapy with tumor-targeted radionuclides may overcome some of these challenges, but

169 tivity enhancements that expand the range of radionuclides measurable by ICP-MS.

170 A more complete record is emerging of radionuclide measurements in fish tissue, sediment, and

171 We have developed a radionuclide methodology and derived reference values fo

172 A radionuclide methodology and reference values have been

173 ty protein (ADAPT) is a promising tracer for radionuclide molecular imaging because of its small size

174 Radionuclide myocardial perfusion imaging (MPI) plays a

175 Heretofore, radionuclide myocardial perfusion imaging has been prima

176 Neptunium-237 is a radionuclide of great interest owing to its long half-li

177 detection of the significant fission product radionuclides of cesium ((135)Cs and (137)Cs) at concent

178 95 mSv a(-1) from combined FDNPP and ambient radionuclides, of which 0.13 mSv a(-1) (14%) was solely

179 ue physicochemical properties, allows vector-radionuclide pairings to be matched to the molecular, pa

180 Besides the long-lived radionuclides plutonium (Pu) and neptunium (Np), which a

181 eement with the abundance of (53)Mn, another radionuclide present in the early solar system and produ

182 n ICP-MS now allows analysis of medium-lived radionuclides previously undertaken using radiometric me

183 ne regarding the monitoring of less volatile radionuclides, pure beta-ray emitters or simply radionuc

184 l plaques/carotid arteries by an experienced radionuclide radiologist and radiographer.

185 s and one of the first analyses of metal and radionuclide reduction in an environmentally relevant Gr

186 liminary linear free energy correlations for radionuclide release performed by Schwantes et al., foll

187 assessed or modeled the distribution of the radionuclides released by the accident at the Fukushima-

188 teractions between natural and anthropogenic radionuclides, seawater, and diverse marine biota provid

189 Radionuclide signals from underground nuclear explosions

190 impurities which have been shown to enhance radionuclide sorption via titanium's influence on the Fe

191 tudies that used CT AC, 12 studies that used radionuclide source AC (RAC), and 15 studies that report

192 CCTA or radionuclide stress myocardial perfusion imaging (MPI).

193 The limitations of clinical and radionuclide studies are then reviewed.

194 follow-up and was further characterized with radionuclide studies consisting of PET-CT and MIBG scint

195 PRIT might be improved using alpha-emitting radionuclides such as (213)Bi.

196 Radionuclides such as those of less volatile elements (e

197 chanism by which volatile and low-volatility radionuclides such as U can reach the environment and sh

198 used nuclear fuel is the release of volatile radionuclides such as xenon and krypton that evolve into

199 ong-lived positron emission tomography (PET) radionuclides, such as manganese-52 ((52)Mn, T(1/2)=5.6d

200 Synthetic radionuclides, such as the transuranic actinides plutoni

201 despite their widespread usage, conventional radionuclide techniques are unable to measure the variab

202 gh in vitro labeled leukocyte imaging is the radionuclide test of choice for complicating osteomyelit

203 (161)Tb is a medium-energy beta(-) radionuclide that is similar to (177)Lu but emits a high

204 ion or biorecovery of Sr or other metals and radionuclides that form insoluble carbonates.

205 Using radionuclides that were naturally present in source wate

206 ssues, and facilitate the use of short-lived radionuclides that would otherwise be incompatible with

207 ndicate that, unlike other Fukushima-derived radionuclides, the (14)C released during the accident is

208 n unprecedented food monitoring campaign for radionuclides, the Japanese government took action to se

209 The nature of interaction between radionuclides, the marine environment, and marine specie

210 diation sensitizers, chemotherapy, and other radionuclide therapies, are being evaluated.

211 -DOTATATE was initiation of peptide receptor radionuclide therapy (14 patients, 27.4%).

212 Peptide receptor radionuclide therapy (PRRT) has become a well-accepted t

213 Peptide receptor radionuclide therapy (PRRT) is a promising treatment for

214 Peptide receptor radionuclide therapy (PRRT) may induce long-term toxicit

215 Lu-DOTA-octreotate (LuTate) peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors.

216 vidualized treatment during peptide receptor radionuclide therapy (PRRT).

217 Targeted radionuclide therapy (TRT) is a branch of cancer medicin

218 e receptor scintigraphy and peptide receptor radionuclide therapy are successfully applied for imagin

219 mprove the safety window of peptide receptor radionuclide therapy by reducing the liver and bone marr

220 PSMA-targeted radionuclide therapy can benefit from serial PMPA comedi

221 ur experience with (177)Lu-PSMA-617-targeted radionuclide therapy in a case series of mCRPC patients

222 ; delineate the position of peptide receptor radionuclide therapy in the therapeutic algorithm for ne

223 Peptide receptor radionuclide therapy is a treatment for inoperable or me

224 d dose calculations in personalized internal radionuclide therapy is directly related to the accuracy

225 ositive recommendations for peptide-receptor radionuclide therapy occurred in observers with low expe

226 (64)CuCl2 as a theranostic agent for PET and radionuclide therapy of malignant melanoma.

227 esponding [(131)I]radiolabeled compounds for radionuclide therapy of melanoma.

228 ne antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistan

229 approach opens the prospect of NIS-mediated radionuclide therapy of metastatic cancer after MSC-medi

230 e receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine tumors and provid

231 e receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine tumors.

232 re powerful tools for diagnostic imaging and radionuclide therapy of various diseases.

233 ommendations for or against peptide-receptor radionuclide therapy require experience and training.

234 These data indicate that systemic radionuclide therapy using (131)I-BA52 as a novel approa

235 radioiodine label creates a precondition for radionuclide therapy using (131)I-labeled HPEM-Cys(59)-A

236 Dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE is based on

237 rs (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled somatostatin ana

238 e receptor scintigraphy and peptide receptor radionuclide therapy using radiolabeled somatostatin rec

239 ions of appropriateness for peptide-receptor radionuclide therapy varied more significantly among obs

240 Radionuclide therapy was conducted with two groups of mi

241 the gatekeeper in addition to bone scanning, radionuclide therapy with (223)Ra may be more effective

242 the gatekeeper in addition to bone scanning, radionuclide therapy with (223)Ra may be more effective

243 uated whether somatostatin receptor-targeted radionuclide therapy with (90)Y-DOTATOC may be a therape

244 In peptide receptor radionuclide therapy with (90)Y-labeled DOTATATE, the ki

245 ars was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, su

246 ever, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agents are promising

247 nt of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemotherapy, and mole

248 ate treatments by surgical approaches and/or radionuclide therapy, chemotherapy, and biotherapy pose

249 ough diagnostic imaging and peptide receptor radionuclide therapy, nuclear medicine has earned a majo

250 (213)Bi (half-life, 46 min) is promising for radionuclide therapy.

251 dneys, creating preconditions for palliative radionuclide therapy.

252 g target for diagnostic imaging and targeted radionuclide therapy.

253 established target for molecular imaging and radionuclide therapy.

254 g parameters of dosimetric importance during radionuclide therapy.

255 umor size was measured to assess response to radionuclide therapy.

256 11B6 in either murine or humanized forms for radionuclide therapy.

257 matched pair of nuclides for PET imaging and radionuclide therapy.

258 t for molecular imaging and peptide receptor radionuclide therapy.

259 ualify for and benefit from peptide receptor radionuclide therapy.

260 entiated thyroid cancer and peptide receptor radionuclide therapy.

261 ing low-energy beta- and alpha-emitters, for radionuclide therapy.

262 ype of therapy (medical vs. peptide receptor radionuclide therapy: 16.0 vs. 26.0 mo; P = 0.014).

263 ctice of NM, clinical molecular imaging, and radionuclide therapy; and suggest a path forward for an

264 med the minerals for reductive scavenging of radionuclides: this has clear implications for the fate

265 s barely shortened, enabling the transfer of radionuclides through an almost-intact food chain.

266 evel measurement of shorter and longer lived radionuclides, thus expanding options for environmental

267 labeled probes have been dual-labeled with a radionuclide to enable cross-validation with nuclear ima

268 limitations by using Cerenkov radiation from radionuclides to activate an oxygen-independent nanophot

269 tories, we confirm the initial source of the radionuclides to the environment to be from active react

270 In this in situ radionuclide tracer test, the environmental behavior of

271 Radionuclide treatment studies showed that the tumor gro

272 Finally, CLI was used to monitor the radionuclide treatment, and the integrated CLI radiance

273 lecules constitute a new class of probes for radionuclide tumor targeting.

274 Of the major organs, the highest radionuclide uptake at 1, 2, and 4 h after injection was

275 Several radionuclides used in medical imaging emit Auger electro

276 , compared with undetectable signal for both radionuclides using the nonbinding control Ab.

277 Serial radionuclide ventriculography and endomyocardial biopsie

278 valuation of Survival Trial measured LVEF by radionuclide ventriculography at baseline and at 3 and 1

279 t with right-sided heart catheterization and radionuclide ventriculography at rest and during exercis

280 vasive hemodynamic monitoring and first-pass radionuclide ventriculography.

281 ryosectioned and the spatial distribution of radionuclides visualized using autoradiography.

282 nd calibration constants determined for each radionuclide-volume combination.

283 The anatomical distribution of the radionuclide was visualized using autoradiography at pre

284 resolution when both a PET and a therapeutic radionuclide were in the PET system.

285 New standardized solutions of each radionuclide were used to determine the response ratios

286 eless, tumor-to-tissue uptake ratios of both radionuclides were comparable, indicating that drug-labe

287 y, the virtues of 12 Auger electron-emitting radionuclides were evaluated in terms of cellular S valu

288 75% of the labile and 59% of the refractory radionuclides were exported from the CEZ with the majori

289 n with the microbially reduced minerals, all radionuclides were removed from solution with U(VI) reac

290 le and there are many data gaps for elements/radionuclides which may need to be considered for risk a

291 uclear repository control the redox state of radionuclides, which in turn has a strong impact on thei

292 atin receptor antagonists and alpha-emitting radionuclides, which may further enhance treatment outco

293 lso produce telltale patterns of short-lived radionuclides, which would be preserved today as isotopi

294 ents that can be radiolabeled with (64)Cu, a radionuclide with a half-life of 12.7 h, ideal for PET i

295 Gallium-68 ((68)Ga) is a generator-produced radionuclide with a short half-life (t(1/2) = 68 min) th

296 +) is a generator of alpha-particle-emitting radionuclides with 4 net alpha-particle decays that can

297 increased interest in theranostics using PET radionuclides with a relatively long physical half-life,

298 radionuclides ((85)Kr, (133)Xe, (135)Xe) or radionuclides with very long half-lives (e.g., (36)Cl, (

299 ionuclides, pure beta-ray emitters or simply radionuclides with very long half-lives.

300 The primary radionuclides within the disposed waste are 239+240Pu an